Abstract
e23151Background: Cancer is a genetic disease driven by heritable or somatic mutations. Diagnosis and classification is moving away from histopathological grading and staging towards molecular categorization of the tumor. Detection of genetic alterations in cancer facilitates selecting targeted therapies, increasing the demand for identifying actionable mutations in clinical specimens. Next-generation sequencing has emerged as a powerful technique to detect genetic variations in oncology samples. Methods: We used Illumina’s investigational Praxis Oncology Panel 15 (OGP) and the MiSeqDx system to analyze molecular alterations in formalin-fixed, paraffin-embedded (FFPE) specimens. We analyzed 140 FFPE samples from different tissues using 20 ng of DNA per sample. Results: The assay results showed an overall 87% success rate; 122/140 samples generated sequencing data. Of 18 unsuccessful samples, one (0.7%) had less than 20 ng of DNA and was excluded from library preparation; 14 (10.1%) failed library QC and w...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
